The Japanese biotech behind Eli Lilly’s new blockbuster obesity pill believes it could be used with an anti-muscle wasting ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing ...

Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and ...

Emrelis wins FDA approval, marking ABBV's first lung cancer drug and strengthening its oncology reach into solid tumors.

The alert comes amid some patients accessing GLP-1RAs through unregulated channels, where safety information is often not ...

No drug is without potential side effects, and there are five major ones that people taking Ozempic, Wegovy or Mounjaro are ...

Diabetes care startup Omada Health went public Friday 14 years after its founding. Here's what its major investors' stakes ...

Excessive weight has been a persistent problem in America, where at least one in five adults in each U.S. state is living ...

According to the clinic, these side effects should be reported to your care team as soon as possible. For Lloyd, only 3 days ...

Eli Lilly lands an $870 million pact with Camurus to build long-acting obesity treatments, tapping FluidCrystalslow-release ...